RESUMEN
OBJECTIVE: The aim: Evaluating serum concentration of IL-17 and IL-23 in autoimmune thyroiditis patient and control group along with the role of CTLA-4 rs3087243 gene polymorphism. PATIENTS AND METHODS: Materials and methods: A case control study was conducted in 30 HT (Hashimoto's thyroiditis), 30 GD (Graves' disease) who attended the consultant clinic for thyroiditis in AL-Diwaniyah teaching hospital and in 30 people as control group. Blood samples were processed for measurement of serum IL-17 and IL-23 using ELISA test. The second part used for DNA extraction then CTLA-4 polymorphism was detected by Allele - specific PCR assay. RESULTS: Results: The level of IL-17, and IL23 was highest in patients with Hashimoto's thyroiditis and Graves' disease, followed by control group and the difference was highly significant (p< 0.001; p< 0.001) respectively; however, the difference between patients Hashimoto's thyroiditis and patients with Graves' disease was not significant (p > 0.05; p > 0.05) respectively. There was no significant association between rs3087243 gene polymorphism and Hashimoto's thyroiditis (p> 0.05), no significant association between rs3087243 gene polymorphism and Graves' disease (p> 0.05). Moreover, there was no significant difference in rs3087243 genotypes frequencies between Hashimoto's thyroiditis and Graves' disease (p> 0.05). CONCLUSION: Conclusions: Serum IL-17 and IL-23 level have been linked with autoimmune thyroiditis disease, while CTLA-4 rs3087243 polymorphism seem to have no role in disease susceptibility in Iraqi population.
Asunto(s)
Antígeno CTLA-4 , Enfermedad de Graves , Enfermedad de Hashimoto , Tiroiditis Autoinmune , Antígeno CTLA-4/genética , Estudios de Casos y Controles , Citocinas , Enfermedad de Graves/complicaciones , Enfermedad de Graves/genética , Enfermedad de Hashimoto/genética , Humanos , Interleucina-17/genética , Interleucina-23/genética , Polimorfismo Genético , Tiroiditis Autoinmune/complicaciones , Tiroiditis Autoinmune/genéticaRESUMEN
OBJECTIVE: The aim: Evaluating the role SNP rs351855 of (FGFR4) gene and estimating the serum concentration of Visfatin cytokine and (HMGB-1) protein in AC patients and in healthy control blood samples. PATIENTS AND METHODS: Materials and methods: Blood samples were collected from 35 patients and 35 healthy controls, and then the serum was used for ELISA test, another each 2 ml blood were used for DNA extraction and rs351855 of (FGFR4) PCR assay. RESULTS: Results: there was no significant difference in mean HMG and mean visfatin among (FGFR4) rs351855 genotypes in patients and control group. There was no significant difference in mean (HMG) among (FGFR) rs351855 genotypes in patients` group (p = 0.923); there was also no significant difference in mean visfatin among FGFR rs351855 genotypes in patients` group (p=0.161) rs351855 genotypes showed that the homozygous GG, heterozygous A/G and homozygous AA. Despite these minor differences there was no significant variation (p = 0.323), also no significant difference in frequency distribution of individuals according to FGFR rs351855 G>A SNP polymorphism between patients` and control groups (p = 0.454). The same was applied to recessive and allelic analysis p>0.05. CONCLUSION: Conclusions: There was no role for (FGFR4) rs351855G/A SNP in disease susceptibility to acute cholecystitis in Iraqi patients. Visfatin cytokine and HMGB-1 protein might act as a good biomarker for diseases.
Asunto(s)
Colecistitis Aguda , Proteína HMGB1 , Citocinas/genética , Predisposición Genética a la Enfermedad , Genotipo , Proteína HMGB1/genética , Humanos , Nicotinamida Fosforribosiltransferasa , Polimorfismo de Nucleótido Simple , Receptor Tipo 4 de Factor de Crecimiento de FibroblastosRESUMEN
The pleiotropic effects of resveratrol include anti-inflammatory, antioxidant, and anticancer activities, and thus unique possibilities exist to explore mechanistic pathways of chemoprevention. The aim of this study was to investigate the role of microRNA (miRNA) alterations induced by resveratrol in the context of chemopreventive mechanisms against dextran sodium sulfate (DSS)-induced colitis-associated tumorigenesis in the Apc(Min/+) mouse. To that end, Apc(Min/+) mice were exposed to 2% DSS to enhance intestinal inflammation and polyp development. Concurrently, mice received either vehicle or resveratrol treatment via oral gavage for 5 weeks. Interestingly, treatment of DSS-exposed mice with resveratrol resulted in decreased number and size of polyps, fewer histologic signs of cell damage, and decreased proliferating epithelial cells in intestinal mucosa compared with vehicle. Resveratrol treatment dramatically reversed the effects of DSS on the numbers of specific inflammatory CD4(+) T cells, CD8(+) T cells, B cells, natural killer T cells, and myeloid-derived suppressor cells in mesenteric lymph nodes. Resveratrol treatment also decreased interleukin-6 (IL-6) and tumor necrosis factor-α protein levels and reduced IL-6 and cyclooxygenase-2 mRNA expression. Microarray analysis revealed 104 miRNAs exhibiting >1.5-fold differences in expression in the intestinal tissue of resveratrol-treated mice. Among them, two miRNAs with anti-inflammatory properties, miRNA-101b and miRNA-455, were validated to be upregulated with resveratrol treatment by reverse-transcription polymerase chain reaction. Pathway analysis revealed that numerous differentially regulated miRNAs targeted mRNAs associated with inflammatory processes with known roles in intestinal tumorigenesis. These results suggest that resveratrol mediates anti-inflammatory properties and suppresses intestinal tumorigenesis through miRNA modulation.